More recently, GLP-1 RA drugs have been approved for weight loss, cardiovascular disease, and chronic kidney disease
Not all of our clients are candidates for weight loss injections, depending on their medical history and general health, and some people may prefer to explore our non-medical weight loss program
SUSTAIN-6 (semaglutide) [53], PIONEER 6 (semaglutide) [61], and LEADER (liraglutide) [54] looked at similar patient populations (over 50 years old with established cardiovascular disease) and found that GLP-1RAs produce a cardiovascular protective function relative to primary endpoints (Table 1)
Understanding how these medications function is essential for optimising their use, including determining the most appropriate time of day for administration to maximise therapeutic benefit and minimise adverse effects
Medication is layered onto a traditional framework centered on tracking, routine, and group accountability, with an emphasis on consistency and adherence rather than ongoing behavior-change coaching
Conjugation to the corresponding peptides was conducted using a general disulfide conjugation protocol
